Thomas Zindrick 0:01 Platinum is such a ubiquitous agent and our lead program is in ovarian cancer. When it works, it works extraordinarily well. Unfortunately, it stops working for far too many patients, and gynecologic oncologists have long referred to the potential to resensitize tumors to platinum as their holy grail.
Speaker B 0:24 Hi, you're listening to Power to the Patients, hosted by Brandon Lee, the podcast for leaders and innovators in pharma and biotech. In each episode, Brandon, the co founder of Power, cuts through the noise to bring real world insights on modern drug development, clinical operations, and the science that drives breakthrough therapies. Because at the end of the day, it's about patients, not just molecules and markets. If you enjoy the podcast, make sure to subscribe and leave a five star rating on Apple, Spotify, or wherever you get your podcasts. Let's get started.
Speaker C 1:01 Welcome to Power to the Patients. I'm your host Brandon Lee and I'm joined today by Tom Zindrick, who is a biotech exec, a life science strategist, and the CEO and president of Genolux Corp. So today we're going to talk about some of the really exciting work that you're doing in oncolytic virus therapies. But before we get there, Tom, maybe just give a quick thumbnail sketch of your career and how you got so excited about the work that you're doing today. ategist, and the CEO and president of Genolux Corp. So today we're going to talk about some of the really exciting work that you're doing in oncolytic virus therapies. But before we get there, Tom, maybe just give a quick thumbnail sketch of your career and how you got so excited about the work that you're doing today.
Thomas Zindrick 1:22 Great. It's a pleasure, Brennan. Really appreciate the opportunity to be here today and talk on your platform and share a little bit about our story. On my backstory, it was not a direct line from where I started to where I am today. As is typical, have an undergrad degree in biology. Then I went to law school, started work as a patent attorney, and while practicing as an attorney I went back and pursued graduate studies in molecular biology. So I would practice during the day and then I would go into the lab at night and work on gels back in the day making single chain bispecific antibodies. So really varied background but it was all directed to ultimately where I landed, where I spent the bulk of my career, which is at Amgen. I joined Amgen in the early 90s in the legal department, starting out as a patent attorney but also assumed business development responsibilities. I was the company sold transactions attorney starting in the mid-90s and built up that group over a decade. I also took on responsibility for the FDA regulatory and compliance within the law department and so had an opportunity to sit on a number of product development teams that went to market working with Some world class drug developers also had the opportunity to work on almost every transaction the company did through logarithmic growth. So it really gave me a broad exposure, an aperture to biotech development and the business of biotech and then my last significant role at amgen. Starting in 2004, the Board of directors approached me and asked me to report in directly to them as the company's first full time chief compliance officer. A company had grown so rapidly and really had outgrown its systems and compliance was becoming much more significant. They asked me to help organize that organization and really develop it into what it is today. So I'm very proud of the work that we did at Amgen. When I joined, probably had 2,000 employees. When I left, we had 20,000. To give you an idea of the growth trajectory that we were on and the opportunities that was really afforded me and others that were part of the company.
Speaker C 3:30 I think one of the things that kind of stands out by that is the transition from legal leading compliance to being the CEO of a biotech. Tell me about that kind of transition and how that happened. were on and the opportunities that was really afforded me and others that were part of the company. I think one of the things that kind of stands out by that is the transition from legal leading compliance to being the CEO of a biotech. Tell me about that kind of transition and how that happened.
Thomas Zindrick 3:41 Again, it really comes down to relationships. Trying to do your best every day and then not really sure where it's going to take you. But usually good things happen. And in this case, after I had left Amgen, I received a call from some former executive leadership team members who were looking at this company in San Diego that I had never heard of Genalox. And they were thinking about joining the board and asked me to go down and really kick the tires on the company for them, get a better understanding of the science, the team and really the development program. And I did that for about six months and it was a great exposure to the company. I was offered the opportunity to become chief Operating officer during that period, but the company was headquartered in San Diego. I was still living and continue to live north of La Thousand Oaks, where Amgen is located. And I had a younger family at the time, so I couldn't make that transition. But. But it did give me the opportunity to not only meet the staff and get to learn a little bit more about the science, which I found absolutely fascinating. But I also was invited to host the 2010 shareholder meeting where I met some key shareholders from that engagement that in 2014 and 15, the board contacted me and asked me if I would be willing to come back as CEO. The company had been up to that point run by the founder scientist who really focused on basic research and the very, very proud of the work that the team did and understanding the Fundamental biology. What the board was really looking for at that point, as is typical in the evolution of any company, biotech or tech or otherwise, was that transition from basic research into translational research and medicine with a go to market strategy ultimately. And I felt with my background I could be of some service and it's just been a phenomenal ride. I've got a fantastic team here, really dedicated individuals who are committed to platform and the patients and that's what drives us every day.
Speaker C 5:37 That's a wonderful tee up. I'd love to maybe just start with the big idea. So what is one big idea that you want listeners to really understand about the work that you're doing at Genellux and the role of oncolytic viruses? ommitted to platform and the patients and that's what drives us every day. That's a wonderful tee up. I'd love to maybe just start with the big idea. So what is one big idea that you want listeners to really understand about the work that you're doing at Genellux and the role of oncolytic viruses?
Thomas Zindrick 5:49 Absolutely. So oncolytic viruses are in the broader category of immunotherapy, which is I think the most exciting development in oncology today. In certain indications it's really helped to bend the survival curves. But it's also been somewhat frustrating because for far too many tumor types where it may otherwise appear that patients immune system should react and respond to attack a cancer that doesn't happen as aggressively as we'd like. And so with what we're doing in the alkalytic virus space and specifically with our lead aspect, our lead agent Olvac, is that think of it as like an off the shelf personalized medicine in the sense that we self manufacture Olivac. It's the same presentation for every patient. But because of the unique aspects and characteristics of an alkaloid virus, we're able to prime and target the patient's immune system to be able to attack the patient's own tumor. Because with tumor heterogeneity every tumor is unique to every patient. And being able to really tailor the immune attack to that patient's own tumor while using a convenient agent that doesn't require excessive engineering and expensive production processes is we think primarily when we think about the oncolytic virus modality. It does three things in a unique way that I don't think any other regions combined as I mentioned, then stimulate an immune response against the tumor. But and all of that creates a local inflammation that remodels the tumor microenvironment and with that conversion of the so called immunologically cold tumor types to the immunologically hot, not only causes that direct and indirect immunotherapeutic attack on the tumor. But what we have found and what we're really pursuing clinically is that during the course of remodeling we can Also resensitize tumors to, to frontline therapies. Our most advanced program, which go into is initially focused on resensitizing tumors to platinum. Platinum is such ubiquitous agent and our lead program is in ovarian cancer. When it works, it works extraordinarily well. Unfortunately, it stops working for far too many patients. And gynecologic oncologists have long referred to resensitized tumors to platinum as their holy grail. And we, through a really, I think, extraordinary set of results in phase two, have positioned ourselves in a, you know, an ongoing phase three to definitively prove that up that we can resensitize tumors. And we're pursuing that not only in cancer, but in a couple of other trials as well. platinum as their holy grail. And we, through a really, I think, extraordinary set of results in phase two, have positioned ourselves in a, you know, an ongoing phase three to definitively prove that up that we can resensitize tumors. And we're pursuing that not only in cancer, but in a couple of other trials as well.
Speaker C 8:35 So much to dig into here. And I want to start at the very top, which is in the grand scheme of cancer treatment. How do you think about cancer immunotherapy versus, let's call like traditional cancer treatments and then within that, I'm curious, what is it about an oncolytic virus that is specifically different from, let's call it the rest of immunotherapy as a category? very top, which is in the grand scheme of cancer treatment. How do you think about cancer immunotherapy versus, let's call like traditional cancer treatments and then within that, I'm curious, what is it about an oncolytic virus that is specifically different from, let's call it the rest of immunotherapy as a category?
Thomas Zindrick 8:56 I see them all ultimately working in a complementary fashion so we can segment them by categories. Mechanisms of action. Because of the unique characteristics of olivac that I've laid out, when I look at other therapeutic agents, My first reaction isn't to think of them as potential competitors. For example, I view them as potential collaborators because of the variety of modes that we can bring to bear on the tumor, the anti tumor activity. It really sets us up to be able to combine. I think what was apparent to me when I joined Genolux is based on early preclinical models. There was a perception, and these are often nude mice, incomplete immune systems. There was often a perception that, you know, oncolytic viruses could carry the whole load. But as we know, complex step to go from animal models into humans. And as we've learned in working with immunocompetent animals, there's the immunity paradox. The body has evolved over the millennia to attack and remove viruses and bacteria. So, so it's drawing that balance of being able to deliver an alkalytic virus that's been genetically engineered to be specific to being an anti cancer agent and to be able to stimulate the immune system while still understanding that the body's constantly trying to stay in a state of homeostasis. And so we've been working in that regard to thread that needle. So I steered within the immunotherapy perspective if you think about the three components, direct cell killing, you can think of maybe a substitute being engineered bacteria, for example, or immune priming, you can think of maybe STING agonists as potential. With respect to the remodeling of the tumor microenvironment and platinum resensitization, I really don't know of a good substitute for that. So I think the really exciting aspect is that there may be individual components that generally could be a proxy for other agents, that none really encapsulates it in the same powerful way that I think the oncolytic virus modality has the potential to do in terms of targeted therapies. And clearly there's been huge progress made in that regard, and those have been really transformational. However, as we know that too often with a targeted therapy, whether it's through escape mutations or some other feedback loop, what can initially be a very pronounced effect can often then turn into aggressive relapse as the tumor evolves or adapts. And in this case for us, we believe because of the ability to prime the immune system and combine with other agents, we're not limited to have a risk of a mutation allowing the tumor to escape. We're coming at it from multiple angles to try to overwhelm the tumor's defenses. sive relapse as the tumor evolves or adapts. And in this case for us, we believe because of the ability to prime the immune system and combine with other agents, we're not limited to have a risk of a mutation allowing the tumor to escape. We're coming at it from multiple angles to try to overwhelm the tumor's defenses.
Speaker C 11:50 One of the things that you mentioned that I love to understand a little bit more about is the personalized nature and the, I guess, requisite manufacturing. Can you help unpack that a little bit? What does that look like? coming at it from multiple angles to try to overwhelm the tumor's defenses. One of the things that you mentioned that I love to understand a little bit more about is the personalized nature and the, I guess, requisite manufacturing. Can you help unpack that a little bit? What does that look like?
Thomas Zindrick 12:00 Absolutely. So in our case, we self manufacture OLVAC at a facility we control in San Diego. It's a closed batch system bioreactor, and we produce the same version of OLVAC with every batch. And when we get the cold chain storage, and then ultimately it is administered to the patient in the clinic. In the case of ovarian cancer, we administer it through a catheter. Intraperitoneal administration, not an uncommon way for chemotherapies to be administered by gynecologic oncologists. In some other studies we have, two other registration path studies we have, we're administering it systemically. So we do have ultimate flexibility in how we deliver ulvimac, the personalized component of this is. So just to unpack a little bit about what happens when the virus infects or is administered. As I mentioned, got to overcome the delivery issues, whether it's the immunity paradox or it's some physical barriers, the extracellular matrix, the hostile environments, whether it's hyposis and the like. But once you do that, in our Case vaccinia. Unlike a number of other viruses, it's a large DNA virus that infects a tumor cell through the membrane. So it doesn't require a biomarker or a receptor, so it allows for a broad spectrum of activity. We've genetically modified ulvivec so that it is attenuated in that we can control its replication cycle. So from a safety perspective, it stays that good balance. Vaccinia is a cytoplasmic virus, and so it effectively brings its own host cell machinery to do its replication by knocking out a key gene, a thymidine kinase gene. As we have done, it then makes the virus dependent upon an abundant abandoned pool of nucleotides. While this modified virus might get into healthy tissue, a, it doesn't have the substrate to replicate, and B, while it's sitting there in a healthy immunocompetent tissue, it gets cleared very rapidly. On the other hand, in a tumor cell, where the virus does have the nutrients to replicate itself, it's really think of it as a trojan horse that cancer cells have disabled the antiviral components to enable the tumor to be cancerous, whether it's P53 or some other host cell components. And as a consequence, the virus takes over the host cell machinery for its own purpose and and replicates. And at a certain point, it causes that host cell to burst, releases not only additional virions, the neoantigens to the immune system, along with the damps in a way that triggers the immune system and through antigen cross presentation, sends these antigens to the immune system. So that tumor is constantly evolving. Those unique neoantigens are presented to the patient's own immune system. And we demonstrated in both preclinical and clinical translational studies that show that we can generate an antitumor T cell response in the blood. We demonstrate that CD8 positive T cells, effector cells, infiltrate into the tumor epithelium. And then with that immune cascade that comes down, what we've learned, and this comes back to really starting to appreciate a virus or optimizing and letting the virus do what it does best, rather than try to put a lot of different bells and whistles on the virus and hope that it alone can eradicate a tumor before the immune system clears it. We really think of it more as a priming for a catalyst or a catalytic event so we don't have to infect every couvir cell, we just have to infect and kill enough tumor cells to activate the immune system. And there comes a point where it's almost a tipping point that we've seen preclinically that when we're able to do that, you see a profound impact on anti tumor activity. Again, what's unique about working with an oncolytic virus is we don't think of administration in a typical PK load perspective because it's a live agent. And there we know that the virus has taken hold, it's formed the beachhead and it's having a profound replicative effect that we ultimately recognize will then stimulate the immune system and again modify certain biological pathways. Maybe if I can't. Just to finish up on that point, the line of clinical data and thinking that we're trying to pursue is we noted from some of our RNA analyses that several of the biological pathways, one in particular in STAT1 has been implicated in platinum resensitization. Tumor fibroblasts, the glutathione pathway can downregulate, which enables the tumor to expel platinum. We showed the ability to upregulate stat 1 in a statistically different way. And we believe that the effector cells, whether those are against the virus backbone, some of the payload proteins, or of course the tumor neoantigens, any of those we believe has the ability to have that reversal effect on the stat1 pathway. And as a consequence what occurs is you get initial viral infection, the immune response, both the direct and the immune cell death. But you also through that set the tumor microenvironment up to be re challenged by platinum. And when re challenging by platinum, when the platinum isn't removed from the tumor, it does two things. It obviously kills tumor cells. It also abrogates a number of the suppressor cells and with that it then will resensitize the memory T cells that were generated from the original Olivec infection. Probably the most profound example I have of that is in our phase two study we had a platinum refractory patient heavily pre treated. And by definition a refractory patient is a patient who on her last exposure to platinum progressed while on drug. So the tumor was absolutely recalcitrant to being treated this patient after a single cycle of Olvax. So patients received doses on two consecutive days, the catheter's removed. That patient went from no response, then responding through 17 cycles, which is a case study in terms of a being able to tolerate the platinum and her quality of life as reported to us was quite high. this patient after a single cycle of Olvax. So patients received doses on two consecutive days, the catheter's removed. That patient went from no response, then responding through 17 cycles, which is a case study in terms of a being able to tolerate the platinum and her quality of life as reported to us was quite high.
Speaker C 18:42 The way this works, and I'm going to explain it as if I have a fifth grade understanding of it because that's about as much as I have. So it sounds like you've developed a virus that specifically replicates in tumor cells and not in healthy cells. When it replicates, the cells burst. This is a tumor killing effect. And then in the bursting of the cell, you then trigger an immune response for the body to then go further target to tumor cells of that kind. I haven't quite caught is what is it about that resensitizes the tumor to platinum?
Thomas Zindrick 19:12 So that's a great question. There's a really elegant paper that was published in cell by a group out of the University of Michigan. And what they demonstrated is in tumor cells that had become platinum resistant, they showed that through tumor fibroblasts and interferon gamma pathway and other chemo and cytokine releases, there would be modification of this stat 1 pathway through glutathione and they were able to reverse that platinum resistance. And so you're exactly right. Through the immune system activation, as I mentioned shown that there are effector T cells that infiltrate into the tumor epithelium. We believe based on connecting a lot of these translational dots, that those affected T cells work exactly the way was shown in the cell paper. They approach the stroma of the tumor and are able to overcome the fibroblast initiated platinum resistance, therefore resensitizing the tumor to platinum, putting it back in its original state and therefore making the tumor susceptible to re challenge. Not only do you get that at typical platinum cytotoxic death, but because of the immune response that you have there, you effectively created a so called hot tumor. And that's why we believe you get this so called prime and boost.
Speaker C 20:43 Fascinating. How should I be thinking about, I guess lines of therapy in a world where you validated like in the phase three that this works as kind of hypothesized, it creates a virtuous cycle with platinum. I help me understand that in terms why we believe you get this so called prime and boost. Fascinating. How should I be thinking about, I guess lines of therapy in a world where you validated like in the phase three that this works as kind of hypothesized, it creates a virtuous cycle with platinum. I help me understand that in terms
Thomas Zindrick 20:58 of the lines of therapy. So in the case of. And this is something that Richard Pasner from FDA just wrote an editorial that was in JAMA where he's pointed out that there now needs to be an appropriate appreciation for the heterogeneity that is caused through multiple lines of chemotherapy or other therapies. Because as we know in our knowledge and thinking about, the tumors have evolved. Every time there's an intervention, the tumor adapts. In our case, what's really exciting is I mentioned earlier, we don't need a biomarker for OLVAC to infect and replicate and kill. We had patients that had between two and nine prior lines with a median of four. And what's really exciting to us is as we look through demographics, patient treatment history, patients, the genomic markers of that patient, and the different lines of therapy or platinum classification, whether it was resistant or refractory, there is a lot of data in response across any metric that we measure, which what we get excited about is while I talk about other therapies potentially being collaborators. So that's where the targeted therapy drive is taking us, is the segmentation of patient populations. In seven completed trials prior to the three that we have ongoing, we treated over 150 patients. Different tumor types, different demographics, different routes of administration. We've never hit an mtd, never. So we believe we are delivering an immunotherapy that at least rivals, if not exceeds the safety it has, that broad spectrum of activity of a general cytotoxic. So we believe we can bring to bear an immunotherapy to that has many of the advantages of the older therapies with the general cytotoxics. And while we are not limited to combining with platinum, I believe we're only starting to scratch the surface. So in one of our other trials in non small cell lung cancer, where we are treating a recurrent population that failed frontline, and we're rechallenging with both platinum and a checkpoint inhibitor because we've shown that we can increase the expression of PD L1 in patients who would otherwise be considered negative. So we think there's an opportunity to catalyze with a variety other agents and effectively our goal would be to become a backbone for a number of different calculations.
Speaker C 23:30 I guess the natural follow up to that is how should we be thinking about tumor types that you are bullish on this being productive for, and tumor types that you're not, how should we be thinking about that? effectively our goal would be to become a backbone for a number of different calculations. I guess the natural follow up to that is how should we be thinking about tumor types that you are bullish on this being productive for, and tumor types that you're not, how should we be thinking about that?
Thomas Zindrick 23:42 So part of it starts with delivery, which are most accessible. There are other later stage oncologic virus programs that are showing great results in skin cancer or in bladder cancer, which tend to be through direct administration. We started in the ovarian space through this intraperitoneal or catheter delivery, because we felt like that would give us an opportunity with a new dosing regimen that we were testing, give us the best opportunity to demonstrate antitumor activity, activity. We were working in a smaller volume and ovarian cancer forms a sheath on the abdomen. So a lot of surface area to put virus on tumor. So really thought we gave ourselves the best opportunity to kind of stack the deck and certainly as borne out, that having been said, in several of those seven completed studies that I've pointed to, we've demonstrated the ability to administer the virus IV or systemically, and in one study in particular in patients with a variety of solid tumors. For those patients in particular who had lung disease, whether it was primary or metastatic, we showed a dose dependent overall survival benefit as a monotherapy in patients that had a median of 5 prior lines with the first pass effect and the high vascularization of the pulmonary circulatory system. We think that gives us again a great entry point into systemic administration. We don't think we're limited there, but we believe that's a great place to start and whether it's ultimately moving from lung cancer. To want to get really creative, think about any patient with a lung net of a solid tumor of any origin, where we can create that beachhead in the lung organ to generate that whole body immune response and go from there. But the virus gets through the entire body. So again, I don't. We're not limited as we move forward, we're thinking about this in a stepwise fashion fashion because we haven't failed a clinical trial yet. I don't want to be the one that does. We're certainly positioning ourselves to be thoughtful. I think ultimately maybe to come back to your question, which I didn't mean to avoid because it's such a target rich environment. If we're going to pursue, and I think the best approach currently is to pursue a combination approach, then to me the next frontier is how do we mix and match combination therapies and that may then dictate where we go from a tumor type. And the reason I say that is in the ovarian study, prior to our moving into the phase 2 with a combination, we were doing a phase 1B dose escalation study as a monotherapy and we were able to get paired biopsies pre and post administration of Olvibec. And it was there that we analyzed, as I mentioned, the generation of antitumor T cell responses, the multiplex ihc, the infiltration of these activated T cells. And when you line those up, what was encouraging was that OLVAC almost consistently was doing what we wanted it to do in every patient. But then when you overlay the clinical response, it didn't match. You couldn't point to the infiltration of T cells. So you think about the paradigm of turning a cold tumor hot and activating the immune system for the infiltration of T cells. Why didn't it work in some Patients versus others. Part of that's the tumor microenvironment. Some of it may be that some patients, platinum isn't the right combination. It might be a checkfront inhibitor, it may be a targeted therapy, it could be whatever. That to me is really the next frontier for us. To me, that's only then creating the next order of questions that are so much bigger than even the ones we're pursuing right now, which is if we want a truly tailored agent as we do, how do we tailor the therapy with other combinations to be effective for the maximum number of patients that we can? ext frontier for us. To me, that's only then creating the next order of questions that are so much bigger than even the ones we're pursuing right now, which is if we want a truly tailored agent as we do, how do we tailor the therapy with other combinations to be effective for the maximum number of patients that we can?
Speaker C 27:48 I'm hearing a lot of things that make this sound perfect, but in any kind of emerging field, any sort of therapeutic platform has fundamental constraints of science, constraints of physics and biolog. What are the constraints or limitations that researchers are staring at that are known constraints? And then what are the constraints that I guess are the ones that I guess you're kind of like waiting for the data cards to turn over that you're thinking through as potential risks here? onstraints of physics and biolog. What are the constraints or limitations that researchers are staring at that are known constraints? And then what are the constraints that I guess are the ones that I guess you're kind of like waiting for the data cards to turn over that you're thinking through as potential risks here?
Thomas Zindrick 28:11 Yeah, I certainly don't want to suggest that this is a panacea. There are many unanswered questions that we're in the process of answering. Some. One of those is the immunity paradox. We want to stimulate the immune system, we want an active immune system. But that same immune system can be called against the virus and remove it, whether it's through complement the innate immune system or antibodies in a way that can blunt its effect. It's kind of a race against time in terms of getting enough virus in to be able to prime the immune system. That's why I like the combinatorial approach. Historically there have been some concerns because of structural physical barriers. Can you get enough virus into the tumor? And oftentimes you'll see patchy infiltration and replication. Another aspect is the lytic activity. The one approved oncolytic virus on the market today is a we use a vaccinia virus. It's a non human pathogen. It was designed as a vaccine. So its backbone was designed to light up the immune system. That's why we think it's an ideal oncologic virus. Other therapies are being used off of or developed off of herpes virus backbones or adena or cold virus backbones whose backbones have evolved over the millennia to evade the immune system. And oftentimes you need to put on pretty strong payload cytotoxic. And that can come with its own challenges. So there are concerns about can you, through the lytic activity, do enough to Stimulate the immune system. We've demonstrated through intraperitoneal administration the infiltration, killing and infiltration of immune cells into the abdomen. We've never found a live virus outside the abdomen, but in patients who had lung mets, malignant pleural effusion, we saw similar dynamic in the health space as we did in the abdominal cavity where you saw that infiltration of immune systems. So you need to have a sufficiently strong lytic priming agent in order to be able to generate that. And as I mentioned, the first, the original and the first approved colonic virus really was effective in the local regional direct injection, but really never demonstrated a strong activity display. That's something that ultimately we're very confident based on our phase two data. But we have a phase three study that we'll read out by the end of the year. It's a randomized trial. Two to one randomization will ultimately wait for the data to prove up, hopefully confirm why we're so excited about where we are currently. Other sort of practical questions come up around handling of the virus. Is it safe? Can it mutate Again? Vaccinia is a large DNA virus. It comes with its own proofreading mechanism. It also is a cytoplasmic virus and so there's no risk of host cell and it needs a tumor in which to replicate. So we do pay close attention to viral shedding. Is there an opportunity through bodily fluids or through pox like lesions to transfect, get in the environment and transfect? That's always a theoretical concern. It's one we watch and we doing viral shedding as part of the phase three study to confirm that's not an issue. And I think maybe the other concerns are around manufacturing and how cost effective can an oncolytic virus be? Historically they've been fairly expensive to manufacture. There are also BSL2SO Biosafety Lab 2 category in the manufacturing setting, certain protections need to be put into place. In the clinic It's Biosafety Lab 1 which is the least considered the safest, but in larger volumes. It's a BSL2 and so we have to be very cognizant of the manufacturing process. But we have a closed loop batch process where we have great sterility, we can control it. And it's a proprietary process that we've implemented in our facility in San Diego where we can scale in a very cost efficient way. So we believe we have addressed many of the concerns around manufacturing and then post Covid because we keep the virus at minus 70 currently cold chain Storage and distribution is always questioned. But post Covid, where almost every center now has a minus 70 freezer for the vaccines and it hasn't been an issue for us at all. So there have historically been a number of concerns and a lot of modalities can be overlooked for a number of years. We believe we're getting to a point where the companies who have stayed the course soon to be addressing many of the impediments that were perceived as real headwinds to oncolytic virus therapy being a significant part of physicians armamentarian. oncerns and a lot of modalities can be overlooked for a number of years. We believe we're getting to a point where the companies who have stayed the course soon to be addressing many of the impediments that were perceived as real headwinds to oncolytic virus therapy being a significant part of physicians armamentarian.
Speaker C 33:00 The thing that I'm left thinking about here, Tom, is the second order effects of this all goes well. In particular, one of the things you described is the resensitization platinum and other potential therapies. And then as a result what happens to status quo of cancer treatment which is so sequential in nature today? : The thing that I'm left thinking about here, Tom, is the second order effects of this all goes well. In particular, one of the things you described is the resensitization platinum and other potential therapies. And then as a result what happens to status quo of cancer treatment which is so sequential in nature today?
Thomas Zindrick 33:18 The way I've been thinking about it is through our clinical studies there are really two redefining goals that I have. One is to redefine the oncolytic virus modality through IV administration, something that has long been understood to fully unlock its potential. And the other is to redefine certain treatment paradigms and platinum resensitization being the first of that. When I look at our phase two data, we're dealing with patients for which there is no standard of care that right now they have physician's choice. Almost every clinical study out there caps the number of prior lines. We start at a minimum of three prior lines and go from there. So we're taking patients who frankly when they enrolled into our trial typically consider to have somewhere between six months and less than a year of survival. In that case, you're often thinking about so called salvage therapy if you will. But in our phase two trial across the platinum refractory and resistant population, we took a patient population that in their immediate preceding line of therapy had a 4.5 month PFS. Had they not joined our trial, historical data would suggest that receiving physician's choice they probably could expect a four month PFS. Our patients had an 11 month PFS. And so we're basically taking all comers most difficult to treat population and giving them a PFS that in some instances El Hair's PFS for a patient population that could have no more than three prior lines and was segmented by being a biomarker was 5.5 months. We doubled that using platinum chemotherapy in this recurrent setting. So to your point, I think we have this opportunity to kind of redefine what late stage means in that regard. And we're doing it with relatively inexpensive chemotherapies. As I mentioned, we've got patients who tolerated chemo extraordinarily well, in part. And I'll give credit to a number of these newer therapies. I do believe because of the improved therapeutic options for patients who have relapsed Frontline platinum, there is a longer time off platinum. Everything we've seen does not suggest that time off platinum means they will do better on platinum subsequently, but it does give the body time recover from that initial platinum treatment. So they're just in a better performance status to be able to then be re challenged with platinum. So I do think there's benefit to that sequence. But from my perspective, our goal would be to take to jump upon approval in this late stage population. It goes directly into frontline. And in fact, during several conversations we've had with the fda, that's exactly what they told us to do. And their point was they see everything. And given what they've seen that we can do in these most difficult to treat patients, they're very excited about what we might be able to do treating patients who are naive to treatment, whose immune systems are intact and whose tumors have not become hostile to therapy because of all these adaptive processes that have been implemented through challenge after challenge of prior lines of therapy. So I think there's an opportunity to effectively transform late stage and potentiate Frontline and basically collapse everything in the middle ultimately. But I think in a way that really helps expand. I don't think it's a zero sum game. I think we're expanding the universe of what we can do for patients. s of therapy. So I think there's an opportunity to effectively transform late stage and potentiate Frontline and basically collapse everything in the middle ultimately. But I think in a way that really helps expand. I don't think it's a zero sum game. I think we're expanding the universe of what we can do for patients.
Speaker C 36:58 That's a powerful vision and I think an appropriate place for us to wrap today. I want to thank you for taking the time to join me on the show and teach me a little bit more about what you and the team are doing over there at Genalox.
Thomas Zindrick 37:09 It's my pleasure, Brandon. I look forward to coming back at some point when I've got data from some of these trials and really digging in to see how close we've come to our hypothesis and where we take the program from there.
Speaker C 37:20 Would love that, Tom. Thanks again.
Thomas Zindrick 37:23 Thank you.
Speaker B 37:27 That wraps up today's episode of Power to the Patients. If you found this conversation valuable, make sure to follow or subscribe so you don't miss the next one.
Speaker C 37:34 1.
Speaker B 37:35 For more insights on drug development, clinical operations and the future of pharma and biotech, connect with us on LinkedIn. Thanks for listening and see you next time.